ALUMIS INC. - COMMON S

Alumis and ACELYRIN Announce Amended Merger Agreement

21 Apr 2025 06:30:00 By Nasdaq GlobeNewswire

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

04 Apr 2025 16:34:51 By Nasdaq GlobeNewswire

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

25 Mar 2025 02:30:00 By Nasdaq GlobeNewswire

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

19 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

Alumis to Present at Leerink's 2025 Global Healthcare Conference

10 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

08 Mar 2025 09:00:00 By Nasdaq GlobeNewswire

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

04 Mar 2025 09:01:00 By Nasdaq GlobeNewswire

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

28 Feb 2025 09:08:33 By Nasdaq GlobeNewswire

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

27 Feb 2025 16:15:00 By Nasdaq GlobeNewswire

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

10 Feb 2025 16:45:50 By Nasdaq GlobeNewswire

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

06 Feb 2025 16:15:00 By Nasdaq GlobeNewswire

Alumis Strengthens Leadership Team with Key Appointments

28 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

19 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

14 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

13 Nov 2024 16:05:48 By Nasdaq GlobeNewswire

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

04 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

27 Sep 2024 09:00:00 By Nasdaq GlobeNewswire

Alumis to Participate in Upcoming September Investor Conferences

03 Sep 2024 16:29:30 By Nasdaq GlobeNewswire

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

13 Aug 2024 16:05:27 By Nasdaq GlobeNewswire

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

29 Jul 2024 08:00:00 By Nasdaq GlobeNewswire